Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
17
×
san diego blog main
17
×
san diego top stories
boston blog main
boston top stories
new york blog main
new york top stories
biotech
san francisco blog main
san francisco top stories
national
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas top stories
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
texas blog main
clinical trials
drugs
san diego
akcea therapeutics
alnylam pharmaceuticals
boston
hereditary transthyretin amyloidosis
inotersen
merck
patisiran
precision medicine
tafamidis
What
medicine
17
×
drug
fda
new
cancer
san
alnylam
approved
bio
cells
diego’s
genomics
precision
roundup
treatment
biotech
disease
event
gene
genetic
goes
help
known
life
long
loss
making
nobel
patients
podcast
prize
rna
rnai
sciences
study
testing
time
uses
way
week
Language
unset
Current search:
medicine
×
" san diego blog main "
×
" national top stories "
×
@xconomy.com
4 years ago
Explore San Diego’s Precision Medicine and Genomics Sector in Xconomy’s New Podcast and Special Report
@xconomy.com
4 years ago
Podcast: How San Diego is Building a Biotech Ecosystem – Genomics & Precision Medicine Experts Weigh in
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Early Bird Sale Ending for San Diego’s Xcelerating Life Sciences Conference
@xconomy.com
4 years ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?
@xconomy.com
6 years ago
Histogen Treatment for Female Hair Loss Cleared for Clinical Testing